Alliance for Aging Research Provides Public Comment to the FDA About COVID-19 Vaccine Development and Administration

Featured image

On October 22, 2020, Alliance for Aging Research President and CEO Sue Peschin provided public comment to the U.S. Food and Drug Administration (FDA) and its Vaccines and Related Biological Products Advisory Committee (VRBPAC) about the Alliance’s position about vaccines to prevent COVID-19. In her comments, Sue emphasized the importance of:

  • older adults taking FDA-approved enhanced (high-dose or adjuvanted) flu products to help protect them during flu season;
  • the FDA understanding geriatric immune response as the agency reviews COVID-19 vaccines;
  • transparency from the FDA, VRBPAC, and all vaccine sponsors about all steps being taken to ensure COVID-19 vaccines are safe and effective for older adults, particularly those 80 and older;
  • taking into account how COVID-19 vaccines will be coadministered with flu or other CDC-recommended adult vaccines.

Read the full comment here.

About the Alliance for Aging Research
The Alliance for Aging Research is the leading nonprofit organization dedicated to accelerating the pace of scientific discoveries and their application to vastly improve the universal human experience of aging and health. The Alliance believes advances in research help people live longer, happier, more productive lives and reduce healthcare costs over the long term. For more than 30 years, the Alliance has guided efforts to substantially increase funding and focus for aging at the National Institutes of Health and Food and Drug Administration; built influential coalitions to guide groundbreaking regulatory improvements for age-related diseases; and created award-winning, high-impact educational materials to improve the health and well-being of older adults and their family caregivers. For more information, visit

Media Contact:

Lauren Smith
Vice President of Communications
[email protected]
(202) 688-1229